JP2009536828A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536828A5
JP2009536828A5 JP2009510183A JP2009510183A JP2009536828A5 JP 2009536828 A5 JP2009536828 A5 JP 2009536828A5 JP 2009510183 A JP2009510183 A JP 2009510183A JP 2009510183 A JP2009510183 A JP 2009510183A JP 2009536828 A5 JP2009536828 A5 JP 2009536828A5
Authority
JP
Japan
Prior art keywords
hla
patient
drug
specimen
drug side
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009510183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536828A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068782 external-priority patent/WO2007134235A2/en
Publication of JP2009536828A publication Critical patent/JP2009536828A/ja
Publication of JP2009536828A5 publication Critical patent/JP2009536828A5/ja
Pending legal-status Critical Current

Links

JP2009510183A 2006-05-11 2007-05-11 薬剤副作用に関連したhlaアレルおよびその検出方法 Pending JP2009536828A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80012106P 2006-05-11 2006-05-11
PCT/US2007/068782 WO2007134235A2 (en) 2006-05-11 2007-05-11 Hla alleles associated with adverse drug reactions and methods for detecting such

Publications (2)

Publication Number Publication Date
JP2009536828A JP2009536828A (ja) 2009-10-22
JP2009536828A5 true JP2009536828A5 (cg-RX-API-DMAC7.html) 2010-06-24

Family

ID=38694734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510183A Pending JP2009536828A (ja) 2006-05-11 2007-05-11 薬剤副作用に関連したhlaアレルおよびその検出方法

Country Status (17)

Country Link
US (2) US7943309B2 (cg-RX-API-DMAC7.html)
EP (1) EP2016198B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009536828A (cg-RX-API-DMAC7.html)
KR (1) KR101450348B1 (cg-RX-API-DMAC7.html)
CN (1) CN101454462A (cg-RX-API-DMAC7.html)
AU (1) AU2007249225B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710436A8 (cg-RX-API-DMAC7.html)
CA (1) CA2651954C (cg-RX-API-DMAC7.html)
DK (1) DK2016198T3 (cg-RX-API-DMAC7.html)
ES (1) ES2422735T3 (cg-RX-API-DMAC7.html)
IL (1) IL194900A (cg-RX-API-DMAC7.html)
MY (1) MY150648A (cg-RX-API-DMAC7.html)
NZ (2) NZ597628A (cg-RX-API-DMAC7.html)
PL (1) PL2016198T3 (cg-RX-API-DMAC7.html)
PT (1) PT2016198E (cg-RX-API-DMAC7.html)
TW (1) TWI335937B (cg-RX-API-DMAC7.html)
WO (1) WO2007134235A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1536021A1 (en) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Method for HLA typing
JP5996524B2 (ja) * 2010-04-12 2016-09-21 アカデミア シニカAcademia Sinica 薬物有害反応に関連するhla複合体を同定する方法
EP2723888B1 (en) * 2011-06-23 2017-01-11 Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung Risk assessment for phenytoin-induced adverse drug reactions
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
US20150225788A1 (en) 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN102660635B (zh) * 2012-01-14 2014-03-12 长沙三济生物科技有限公司 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒
CN103114138B (zh) * 2013-01-27 2014-12-03 复旦大学 Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒
US10041121B2 (en) * 2013-09-17 2018-08-07 Agency For Science, Technology And Research Method for detection of a genetic variant
CN104017898B (zh) * 2014-06-25 2016-04-27 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
CN104232781B (zh) * 2014-09-26 2017-04-19 陕西佰美基因股份有限公司 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法
CN106119362B (zh) * 2016-06-30 2019-09-10 江苏伟禾生物科技有限公司 一种用于检测hla-b*1502等位基因的引物组及试剂盒
CN108929902B (zh) * 2018-07-28 2022-03-25 北京博奥晶典生物技术有限公司 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法
CN109355358A (zh) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法
CN109554460B (zh) * 2018-12-17 2022-03-22 上海市疾病预防控制中心 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途
SG11202111473UA (en) * 2019-05-06 2021-11-29 Chang Gung Memorial Hospital Linkou Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof
CN111620924A (zh) * 2020-06-04 2020-09-04 华中农业大学 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用
CN113308532A (zh) * 2021-05-28 2021-08-27 上海康黎诊断技术有限公司 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒,以及方法
WO2023080478A1 (ko) * 2021-11-02 2023-05-11 주식회사 랩 지노믹스 Hla-b*5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
WO1994021818A1 (en) 1993-03-18 1994-09-29 N.V. Innogenetics S.A. Process for typing hla-b using specific primers and probes sets
US5550039A (en) 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2004071152A2 (en) * 2003-02-17 2004-08-26 Novartis Ag Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions

Similar Documents

Publication Publication Date Title
JP2009536828A5 (cg-RX-API-DMAC7.html)
JP6815372B2 (ja) 疾患危険因子を同定する方法
Kim et al. The human leucocyte antigen‐DRB1* 1302‐DQB1* 0609‐DPB1* 0201 haplotype may be a strong genetic marker for aspirin‐induced urticaria
CN102586408B (zh) 高血压易感基因Mfn2单核苷酸多态性位点rs3820189的检测方法及检测试剂盒
JP2012531195A5 (cg-RX-API-DMAC7.html)
JP2013178260A5 (cg-RX-API-DMAC7.html)
TW200844238A (en) HLA alleles associated with adverse drug reactions and methods for detecting such
JP2018518147A5 (cg-RX-API-DMAC7.html)
Jern et al. A reassessment of the possible effects of the serotonin transporter gene linked polymorphism 5-HTTLPR on premature ejaculation
Carapito et al. On the genetics of the Silk Route: association analysis of HLA, IL10, and IL23R-IL12RB2 regions with Behçet’s disease in an Iranian population
Tran et al. Association between AGT M235T and left ventricular mass in Vietnamese patients diagnosed with essential hypertension
JP2018504909A5 (cg-RX-API-DMAC7.html)
Kim et al. HLA-B27 homozygosity has no influence on radiographic damage in ankylosing spondylitis: Observation Study of Korean spondyloArthropathy Registry (OSKAR) data
Sousa et al. Relationship between ADD1 Gly460Trp gene polymorphism and essential hypertension in Madeira Island
JP6857130B2 (ja) Crhr1拮抗薬を用いた治療に対する反応の遺伝子予測因子
CN104630339B (zh) 用于急性冠脉综合征早期诊断的循环miRNAs及其应用
Pascual et al. Pharmacogenetics of asthma
JP2017512204A5 (cg-RX-API-DMAC7.html)
CN101886129B (zh) 高血压易感基因AGTR1单核苷酸多态性位点rs388915的检测方法及检测试剂盒
Prabakaran et al. The human genetic variant rs6190 unveils Foxc1 and Arid5a as novel pro-metabolic targets of the glucocorticoid receptor in muscle
Tani et al. Polymorphism analysis of the upstream region of the human N-methyl-D-aspartate receptor subunit NR1 gene (GRIN1): implications for schizophrenia
Schmuczerova et al. Genetic variability of HVRII mtDNA in cord blood and respiratory morbidity in children
Zhang et al. Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene rs4073259 polymorphism not associated with ischemic stroke in the Northeastern Chinese Han population☆
Oosterveer et al. 5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia
Jiang et al. Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan